Delivery Order SPE2DB22D3004-SPE2DB25FSB67
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 15, 2025. This firm fixed-price, non-set-aside delivery order, which is due for completion by September 16, 2025, represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $3,537.17 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mounjaro (tirzepatide) 5 mg/0.5 mL pens in 0.5 mL unit doses. The contract, which is a non-set-aside competitive award with an ultimate completion date of July 25, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,904.63 to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 15 mg/0.5 ml pens on July 22, 2025, with completion scheduled for July 23, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a GLP-1 receptor agonist used for diabetes management, representing part of...
- The Defense Logistics Agency awarded a delivery order valued at $4,645.08 to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 10 mg/0.5 mL pens on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed-price pricing and represents a single delivery order for the diabetes medication to support federal healthcare needs. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $1,632.54 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 mL pens with a completion date of July 22, 2025. This firm fixed price delivery order is unclassified with no set-aside provisions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a GLP-1 receptor agonist indicated for diabetes management, representing part of the...
- The Defense Logistics Agency awarded a $48,976.20 delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 10 mg/0.5 mL pen injections on September 12, 2025, with completion targeted for September 15, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Mounjaro is a GLP-1 receptor agonist medication used for diabetes management,...
- The Defense Logistics Agency awarded a $11,495.12 delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 5 mg/0.5 mL pens on May 27, 2025, with completion scheduled for May 28, 2025. This competitively awarded, firm fixed-price contract requires delivery to the company's facility in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and...
- The Defense Logistics Agency awarded a $8,682.80 delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 15 mg/0.5 mL pens on July 14, 2025, with completion expected by July 15, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a delivery order valued at $1,170.98 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 12.5 mg/0.5 mL pen injections on August 29, 2025, with completion scheduled for September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through the federal procurement process. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $6,235.50. This competitively awarded, firm fixed-price delivery order was issued on August 4, 2025, with an ultimate completion date of August 5, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation,...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FSB67Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 10 mg/0.5 mL pens on August 20, 2025, with a ceiling value of $1,075.33 and an ultimate completion date of August 21, 2025. This competitively awarded, firm fixed-price delivery order was placed without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Mounjaro is a widely used diabetes medication, consistent with AmerisourceBergen's extensive portfolio of pharmaceutical products supplied to federal healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As the prime contractor on this comprehensive pharmaceutical support vehicle, AmerisourceBergen serves as a critical distributor of medications, vaccines, medical devices, and specialized healthcare commodities to military healthcare programs, the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems on a global basis. The company's substantial federal contract portfolio demonstrates its established capability to meet competitive federal procurement requirements across multiple therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 8/20/25 |